ALK and non-small cell lung carcinoma: It is well acknowledged that single-agent bevacizumab21 or pemetrexed22 is effective as the continuation maintenance therapy in patients with nonsquamous Non-Small Cell Lung Cancer (NSCLC) (who are negative for sensitizing EGFR mutations or Anaplastic Lymphoma Kinase arrangements) beyond 4 to 6 cycles of initial therapy.